Floatz logo

Lumateperone

Manic Bipolar Affective Disorder

Intra-Cellular Therapies, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Manic Bipolar Affective Disorder cohort.

Asset / SponsorPhaseRating
Risperdal
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
LITHIUM, ELEMENTAL
University of Cincinnati
Phase 4BBB
Seroquel®
University of Cincinnati
Phase 4BBB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
Allopurinol
Sheba Medical Center
Phase 4BB

View all 27 →

Same molecule, other indications

Lumateperone is also rated in:

schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
bipolar depressionDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →